# The Bonebridge Active Bone Conduction Hearing Implant: Safety, Effectiveness and Outcomes Based on 355 Patients

## TL;DR

This study shows that the Bonebridge hearing implant is safe and effective for treating various types of hearing loss in 355 patients.

## Contribution

The study presents the largest cohort analysis of Bonebridge implants, confirming their safety and effectiveness.

## Key findings

- Significant hearing improvement was observed in patients with conductive, mixed, or unilateral hearing loss.
- The APHAB questionnaire showed improved subjective hearing function post-implantation.
- A low complication rate of 4.8% was reported, with successful reimplantation in most cases.

## Abstract

This study evaluates the safety and efficacy of the Bonebridge BCI 601 and 602 bone conduction implants in our largest cohort to date of 355 patients. The patients had a wide age range and exhibited conductive, mixed, or single‐sided deafness (SSD).

All patients underwent Bonebridge implantation. Pre‐ and post‐implantation evaluations included pure‐tone audiometry, speech recognition tests, and free‐field audiometry. Word recognition was measured using the Polish Monosyllabic Word Test, while speech reception in noise was assessed using the Polish Sentence Matrix Test. Subjective benefit was assessed using the APHAB questionnaire. Follow‐up tests were performed 3–6 months after activation.

Revision surgery was required in 17 patients (4.8%) due to complications, including implant removal in 5 cases. Reimplantation was successful in 4 of these. The APHAB questionnaire showed improved hearing function and all hearing tests also showed significant improvement.

Active bone conduction implantation is an effective method for the rehabilitation of conductive hearing loss, mixed hearing loss, and unilateral deafness. This large cohort study confirms significant hearing improvement and subjective benefits. The low complication rate supports the reliability of the Bonebridge system.